Alumis (ALMS) Expected to Announce Earnings on Wednesday

Alumis (NASDAQ:ALMS) is expected to be announcing its earnings results before the market opens on Wednesday, February 12th. Analysts expect the company to announce earnings of ($1.36) per share for the quarter.

Alumis Price Performance

Shares of NASDAQ:ALMS opened at $7.45 on Wednesday. Alumis has a 12-month low of $6.29 and a 12-month high of $13.53. The business has a 50-day moving average price of $8.02 and a 200 day moving average price of $10.36.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Baird R W upgraded shares of Alumis to a “strong-buy” rating in a research report on Thursday, October 31st. HC Wainwright reiterated a “buy” rating and issued a $26.00 target price on shares of Alumis in a report on Monday, January 6th. Robert W. Baird began coverage on Alumis in a research report on Thursday, October 31st. They issued an “outperform” rating and a $25.00 target price on the stock. Oppenheimer began coverage on Alumis in a research report on Thursday, January 30th. They set an “outperform” rating and a $32.00 price target for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a report on Thursday, November 14th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $27.57.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.